Stem Cell Therapy for Meniscus and ACL Injuries

Meniscus tears and anterior cruciate ligament (ACL) injuries are among the most common knee injuries, and both are notoriously slow to heal because the tissue involved has limited blood supply. This article looks at where mesenchymal stem cell (MSC) therapy actually stands for these injuries — including a genuinely encouraging Japanese phase III trial on meniscus repair, a far more cautious picture for ACL augmentation, and the important distinction between stem cell therapy and the more commonly marketed platelet-rich plasma (PRP) injections.

The meniscus is a C-shaped cartilage cushion that absorbs shock in the knee, while the ACL is a central stabilizing ligament. Both structures — especially the inner two-thirds of the meniscus and the ACL itself — have poor natural blood flow, which is a major reason surgical repairs sometimes fail to heal and why researchers have been investigating whether stem cells can improve the odds. It's worth being clear from the outset: stem cell therapy is not the same as PRP. PRP concentrates a patient's own platelets and growth factors from blood and is already used fairly widely in sports medicine clinics. Stem cell therapy, by contrast, involves live mesenchymal cells — harvested from bone marrow, fat, or joint (synovial) tissue — that are injected or implanted with the goal of directly contributing to tissue repair. The two are frequently confused in clinic marketing, but the evidence base for each is quite different.

How It's Thought to Work

MSCs are thought to help meniscus and ligament healing through a few proposed mechanisms: differentiating into cartilage- or connective-tissue-like cells, secreting growth factors and anti-inflammatory signals that support the body's own repair process, and potentially improving blood supply to the poorly vascularized zones where tears occur. In meniscus research, synovial-tissue-derived MSCs have received particular attention because synovium is a source of cells naturally suited to joint tissue and is relatively easy to biopsy arthroscopically. In ACL research, MSCs or bone-marrow concentrate have mostly been studied as an add-on at the time of surgical reconstruction, with the hope of improving graft healing and integration rather than as a stand-alone treatment.

What the Evidence Shows

The most notable recent data point is a 2026 phase III multicenter trial from Japan (Sekiya, Uchio, and colleagues, published in the Journal of Orthopaedic Science), which combined arthroscopic meniscal suturing with a later injection of the patient's own cultured synovial MSCs for meniscal flap tears. In the main cohort of 15 patients, knee function (Lysholm score) improved by an average of roughly 54 points at one year — comfortably clearing the study's pre-set success threshold — and gains were sustained at two years, with the large majority showing arthroscopic or MRI evidence of healing. That's a genuinely promising result. The important caveat: this was a small, single-arm, open-label study with no control group, so it cannot show how much of that improvement is attributable to the stem cells versus the surgical repair and rehabilitation itself, and it needs to be confirmed in a larger, controlled trial before it changes practice.

The broader picture for meniscus tears, per a 2021 systematic review in the European Review for Medical and Pharmacological Sciences, is that most clinical evidence so far comes from only a handful of small studies (five clinical studies were identified), which generally reported favorable safety and outcome signals but left the reviewers unable to say which cell source or delivery method works best, calling instead for larger randomized trials with longer follow-up.

For ACL reconstruction, the evidence is notably weaker. A 2022 systematic review in Arthroscopy: The Journal of Arthroscopic & Related Surgery concluded plainly that "augmentation of ACL surgery with cellular therapy is not currently evidence based." Of the four qualifying clinical studies, bone marrow concentrate and fat-derived cell treatments showed no clear benefit over standard reconstruction, while a couple of other cellular approaches showed more promise — but overall study quality was rated only moderate, with just one study at low risk of bias.

No stem cell product is FDA-approved for meniscus or ACL treatment. Clinics offering these injections in the U.S. are providing an unapproved, investigational therapy, and the FDA has issued warning letters to businesses marketing unproven stem cell products.

Who Might Be a Candidate

• Patients with a reparable meniscal flap or degenerative tear being treated with arthroscopic suturing, where MSC augmentation is being studied as a healing aid rather than a replacement for surgery
• Younger, active patients whose meniscus tissue and blood supply give repair a realistic chance of success
• Patients enrolled in a registered clinical trial with informed consent and appropriate oversight, rather than a direct-to-consumer injection clinic
• Patients who understand this is not a substitute for ACL reconstruction, which remains the evidence-based standard of care
• Patients without active infection, uncontrolled inflammatory disease, or other contraindications to cell-based procedures, as determined by an orthopedic specialist

Bottom Line

Stem cell augmentation of meniscus repair is one of the more genuinely encouraging stories in orthopedic regenerative medicine right now, with real phase III trial data showing strong, durable improvement in knee function after combining surgical repair with synovial MSC injection. But it is still early: the pivotal trial was small and lacked a control group, and the broader literature calls for bigger, randomized studies before this becomes routine care. For ACL reconstruction, current systematic review evidence does not yet support adding cellular therapy to standard surgery. In both cases, no product is FDA-approved for this use, and PRP — a different and more established treatment — should not be confused with stem cell therapy when discussing options with a surgeon.